Mylan N.V. CEO Heather Bresch, fresh off last week’s congressional grilling over the EpiPen price hikes, is now fielding questions from U.S. Sen. Patty Murray, D-Washington, about a 2012 settlement with Teva Pharmaceutical Industries Ltd. that “may resemble” a “pay for delay” agreement, in Murray’s words.
Murray wrote Bresch on Tuesday asking for details of the 2012 settlement between Teva and Pfizer Inc., whose subsidiary manufactured the EpiPen for Mylan. Pfizer brought the patent-infringement suit against Teva that led to the settlement agreement. The agreement required that Teva not launch a generic version of the life-saving epinephrine auto-injector until June 2015. The exact terms of the agreement are unknown, Murray said. A Mylan spokeswoman said they are confidential.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
